

## Modified de Gramont Regimen + CETUXimab (Infusional 5-FU / Leucovorin / CETUXimab)





Name: Nationality: Gender/Age:	File #: Civil ID: DOB:	Ht (cm): Wt (Kg): BSA (m²):				
Indication(s): Advanced stage colorectal cancer.         Central line: □ Available □ NA       Allergies: □ NKA □ Yes, specify;						
Parameters: Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min.						
Pre-treatment Medications: (30-60 min before starting treatment)						
Ondansetron 8 mg PO/IV						
Dexamethasone 10 mg PO/IV	,					
Standard Protocol:						

DRUG	DOSE	ADMINISTRATION	DAYS
Leucovorin	200 mg/m <sup>2</sup>	IV In 250 mL NS over 2 hr.	D1
5-FU (bolus)	400 mg/m²	ForIV In 250 mL NS over 15 min.	D1
5-FU (infusion)	2400 mg/m²	For outpatient: continuous infusion via 5-FU pump or For inpatient: IV in 1000 mL NS over 46 hr	D1, 2
CETUximab	500 mg/m²	IV undiluted over 2 hr. Then, flush the IV line with 50 mL NS at end of infusion.	D1
To be repeated e	very 2 week until	disease progression or intolerable toxicity.	

Special instructions: The appropriate Dose Band INFUSOR for 5-FU will be applied accordingly.

## **Treatment Description:**

Cycle	Day	Date	Leucovorin	5-FU (bolus)	5-FU (inf.)	CETUximab	Physician	Consultant
C#	D1							
	D2		xxxxxxx	xxxxxx		xxxxxxx		

Important Notes:  Reported grade 3/4 toxicities: □ None □ He	matological □ Non-Hematological	
If yes; Did it indicate hospitalization?	☐ Yes ☐ No	
Did it indicate chemo-delay for ≥ 7 days?	☐ Yes ☐ No	
Did it indicate dose reduction?	☐ Yes ☐ No	
Did it indicate G-CSF support?	☐ Yes ☐ No	
ANTI-CANCER TREATMENT PREPRINTED ORDER, V2	Approved: 01/Feb/2017 Reviewed: 01/Apr/2020	Printed: 17/Jun/2020